Abstract
Abnormal accumulation of misfolded proteins in the endoplasmic reticulum and their aggregation causes inflammation and endoplasmic reticulum stress. This promotes accumulation of toxic proteins in the body tissues especially brain leading to manifestation of neurodegenerative diseases. The studies suggest that deregulation of proteostasis, particularly aberrant unfolded protein response (UPR) signaling, may be a common morbific process in the development of neurodegeneration. Curcumin, the mixture of low molecular weight polyphenolic compounds from turmeric, Curcuma longa has shown promising response to prevents many diseases including current global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and neurodegenerative disorders. The UPR which correlates positively with neurodegenerative disorders were found affected by curcumin. In this review, we examine the evidence from many model systems illustrating how curcumin interacts with UPR and slows down the development of various neurodegenerative disorders (ND), e.g., Alzheimer’s and Parkinson’s diseases. The recent global increase in ND patients indicates that researchers and practitioners will need to develop a new pharmacological drug or treatment to manage and cure these neurodegenerative diseases.
Introduction
The global burden of neurological diseases are rising, and considered as one of the leading causes of mortality and disability across the globe (Gammon, 2014; Feigin et al., 2019). The correct folding and packaging of the proteins are essential in regulation of many neurological diseases. All proteins bound to organelles and extracellular spaces are subject to proteostasis (Wang and Kaufman, 2016).
The abundance of too many secretory proteins in the endoplasmic reticulum (ER) induces the unfolded protein response (UPR) and in case of chronic ER-stress this leads to apoptotic cell death (Taniguchi and Yoshida, 2011; Hetz et al., 2013; Shah et al., 2015; Figure 1). Thus, the UPR protects cells against deformed proteins and maintains cellular homeostasis (Smith and Mallucci, 2016). There are three signal transducers inside the ER, which are inositol requiring enzymes 1 (IRE1) α and β, protein kinase R-like ER kinase (PERK) categorized as type I, and activating transcription factor 6 (ATF6), α and β as type II (Shah et al., 2015; Hetz and Papa, 2018). Various transcription factors activate these signal transducers to restore proteostasis and enhance ER and Golgi biogenesis (Hetz et al., 2020). Neurodegenerative diseases (NDs) are characterized by the degeneration and death of neurons (Pohl et al., 2018). While, the misfolded proteins cause ER-stress-induced neuronal apoptosis in progressive neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD) (Hetz and Mollereau, 2014; Scheper and Hoozemans, 2015; Figure 1). AD which accounts for 60–80% and other forms of dementia are the world’s fifth leading cause of death, and its prevalence is expected to triple by 2050, according to WHO (Voulgaropoulou et al., 2019). While, PD is the most common neurodegenerative disease (20–30%) after Alzheimer’s, with a prevalence of 150/100,000 (Schapira, 1999).
FIGURE 1
A schematic representation of interplay of curcumin, UPR and factors of Alzheimer’s disease and Parkinson’s disease. The yellow highlighted genes, component and pathway represents the effect of Curcumin. The star shape (yellow) denotes curcumin. Green arrow shows signaling pathway for PD while Blue of AD. ER, endoplasmic reticulum; IRE1, inositol requiring enzymes 1; PERK, protein kinase R-like ER kinase; ATF4, Activating transcription factor 4; ATF6, Activating transcription factor 6; CHOP, C/EBP Homologous Protein; elF2a, Eukaryotic translation initiation factor 2 alpha.
Curcumin, a primary natural polyphenol derived from Curcuma longa rhizome is found affecting a number of diseases including current SARS-CoV-2 infection (Gupta et al., 2013; Noorafshan and Ashkani-Esfahani, 2013; Marton et al., 2020; Sharifi-Rad et al., 2020; Ahmadi et al., 2021). The antioxidant, anti-inflammatory, anti-mutagenic, anti-parasitic, antimicrobial and anti-cancerous properties of curcumin are quite explored (Reddy et al., 2005; Aggarwal and Harikumar, 2009; Gupta et al., 2013; Vera-Ramirez et al., 2013; Lestari and Indrayanto, 2014; Hewlings and Kalman, 2017). Recently curcumin was characterized as a pharmacophore by X-ray micro-crystallography of fiber-forming tau fragments with small molecule binders, binding to the β-pleated layer in tau’s paired helical filaments (Landau et al., 2011). Reports suggest that curcumin further scavenges the toxic reactive oxygen species (ROS) and increases Superoxide dismutase (SOD), Na+-K+ ATPase, catalase, glutathione, and mitochondrial complex enzyme levels (Reeta et al., 2010; Barzegar and Moosavi-Movahedi, 2011; Li et al., 2020). It also reduces lipid peroxidation by reducing Malondialdehyde, nitrite, and acetylcholinesterase (Abdel-Diam et al., 2019; Kheirouri and Alizadeh, 2019). Curcumin affects neurogenesis in brain regions involving the Canonical Wnt/-Catenin Pathway (Tiwari et al., 2014). It activates nuclear factor erythroid 2-related factor (Nrf2), the antioxidant master regulator, to protect dopaminergic neurons (Dong et al., 2018). Furthermore, curcumin increases the expression of β-tubulin, neuroD1, doublecortin, neurogenic, neuroligin, and neuregulin while decreases the expression of the signal transducer and activator of transcription 3 (STAT3) (Karlstetter et al., 2011). Curcumin further helps in inhibition of neuroinflammation possibly by binding to the sensile plaques, inhibiting Aβ plaque aggregation, plaque pathology, and decreasing amyloid levels (Lim et al., 2001; McClure et al., 2017; Mei et al., 2020). It also inhibits several dysregulated cell-signaling pathways (Su et al., 2020; Ege, 2021). Curcumin also safeguards against AD (Desai and Patravale, 2018; Nebrisi et al., 2020). Recently, curcumin and curcuminoids were reported as a promising candidate against NDs (Gregory et al., 2021; Ryskalin et al., 2021; Silvestro et al., 2021; Simeonova et al., 2021). Here we review the curcumin’s potential role in NDs and UPR regulations. Given the volume of literature, we chosen to focus on with common NDs like AD and PD in relation to UPR.
Unfolded Protein Response and Neurodegenerative Diseases: A Common Connection and Consequences
UPR activation has been observed in many NDs (Scheper and Hoozemans, 2015). Activated astrogliosis, brain aggravation, and microglial multiplication cause ADs (Haass and Selkoe, 2007). The amyloid-β (Aβ) peptide aggregates in specific brain areas like the neocortex, hippocampus, and limbic region which further causes synaptic failure and neuronal death (Chyung et al., 2005). UPR is a cellular stress reaction caused by misfolded proteins in the ER, while misfolded proteins accumulate in PD (Taylor et al., 2002). Thus, the UPR is linked to PD in cell models (Hoozemans et al., 2007). In PD, Lewy bodies and protein incorporation in neurites were increased (Mahul-Mellier et al., 2020). Synuclein, a small presynaptic protein, is a major component of Lewy bodies (Clayton and George, 1999; Breydo et al., 2012). The PD patients were also found correlated with higher levels of pPERK, peIF2, and pIRE1 than non-neurological controls (Hoozemans et al., 2007). pPERK-positive neurons had increased diffuse cytoplasmic synuclein immunoreactivity. These findings suggest a link between synuclein accumulation and ER stress in dopaminergic neurons. Further, heat shock reactions and ER or mitochondrial unfolded protein reactions are examples of misfold UPR (Lee et al., 2011; Kakkar et al., 2014; Chiti and Dobson, 2017; Shamsi et al., 2017). By upregulating atomic chaperones and proteasome components, the authors reported the increase in the ability to unfold and refold misfolded proteins, as well as eliminate misfolded proteins (Ciechanover and Kwon, 2017).
Curcumin and Neurodegenerative Diseases: Interventions and Modalities
This section reviews curcumin’s use and effects on NDs, while focusing on PD and AD. Curcumin’s neurological effects make it one of the most promising natural therapies for AD (Noorafshan and Ashkani-Esfahani, 2013; Eghbaliferiz et al., 2020). The lower prevalence of AD in India among adults aged 70–79 years (4.4 times lower than in the US) is attributed to higher curcumin use (Ganguli et al., 2000; Yang et al., 2005). Curcumin’s ability to bind to Aβ-pleated structure reduces plaque stress in most AD plaque pathogenesis models (Yang et al., 2005; Garcia-Alloza et al., 2007; Cheng et al., 2013). Curcumin is also known for directly binding and inhibiting the aggregation of Aβ-sheet conformations found in many NDs (Cole et al., 2007; Mishra and Palanivelu, 2008; Forouzanfar et al., 2020; Radbakhsh et al., 2021).
Curcumin inhibits tau aggregation by binding to neurofibrillary tangles (Brunden et al., 2010; Mohorko et al., 2010; Mutsuga et al., 2012). Several β-pleated layer complexes, such as huntingtin, prion aggregates and α-synuclein, are found interacting with curcumin (Caughey et al., 2003; Ono et al., 2004; Pandey et al., 2008). Curcumin interacts directly with heat shock proteins (HSPs), such as HSP90 and HSP70, in Aβ-infused rats, tau transgenic mice and human models (Ma et al., 2013). It affects phagocytic cell association with plaque structures and stimulates clearance of Aβ aggregates in human cell lines and rodent AD models, similar to the amyloid vaccine (Frautschy et al., 2001; Cole et al., 2004). Curcumin also inhibits NF-κ B and Activator Protein 1 (AP1). A dysfunctional transcription factor pathway limits the resolution of inflammation in AD. Curcumin’s inhibition of AP1 transcription results in hyperphosphorylation of tau (Singh and Aggarwal, 1995; Xu et al., 1997; Cho et al., 2007). According to recent research, curcumin seems to decrease peroxisome proliferator activated receptor (PPAR) activation by inhibiting Toll-like receptor 4 complex homodimerization. Wang et al. (2010) report that curcumin directly increases PPAR expression. The PPAR forms heterodimers with Retinoid X receptor alpha to control microglial activation and phagocytosis (Heneka et al., 2005). PPAR inhibits pro-inflammatory cytokines that promote tau kinase hyperactivity, pTau buildup, and oxidative damage. Curcumin also promotes oligodendrocyte progenitor (OP) differentiation and inhibits tumor necrosis factor-induced OP maturation arrest through PPAR (Bernardo et al., 2021). Curcumin directly inhibits β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), which catalyzes the N terminal cleavage of transmembrane amyloid precursor protein (APP) (Lin et al., 2008), which further indirectly inhibits BACE1 (Huang et al., 2020). Curcumin also reduce Aβ levels by delaying APP maturation in the secretory route (Zhang et al., 2010). The anti-inflammatory properties of curcumin have been linked to improved learning and memory in ApoE4 mice (Kou et al., 2021).
Curcumin combats AD in various ways, according to recent research (Serafini et al., 2017; Su et al., 2020). It inhibits the production of β-amyloid, tau, and acetylcholinesterase, controls microglia, and chelates metals (Tang et al., 2017; Voulgaropoulou et al., 2019). Curcumin binds to Aβ and inhibits harmful aggregate formation (Ono et al., 2004; Kim et al., 2005; Yang et al., 2005). However, the diketone bridge in curcumin is not necessary for curcumin’s anti-inflammatory actions, since reduced curcumin (tetrahydro curcumin) has strong anti-inflammatory characteristics (Begum et al., 2008). By deactivating Glycogen synthase kinase 3 (GSK-3), it reduced Aβ generation and plaque formation by downregulating the ROS/JNK pathway. Curcumins inhibition of BACE1 by GSK3 resulted in reduction of Aβ plaques (Durairajan et al., 2012). The precise means by which curcumin regulates these processes are unknown. It seems like that curcumin is a potential antioxidant for treating AD, and that combining carriers and targeting agents to enhance brain delivery is highly effective. In future, more research on curcumin’s mechanism of action related to NDs are required.
Interplay of Curcumin and Unfolded Protein Response
The ER has vital cellular functions including protein folding, post-translational modification, protein translocation, lipid synthesis, and Ca2+ storage (Schwarz and Blower, 2016). Under ER-stress, evolutionarily conserved UPR response system corrects ER homeostasis by activating transcription factors (ATF4, ATF6, and XBP1) that inhibit protein translation, and promotes unfolded protein destruction (Zhao and Ackerman, 2006; Limonta et al., 2019). In cases of persistent ER stress, the UPR initiates intrinsic apoptotic pathway and cell death (Sano and Reed, 2013). UPR may also be triggered by non-ER stress associated mechanisms (Hetz et al., 2020). For example, vascular endothelial growth factor signaling promotes angiogenesis through the UPR pathway (Urra and Hetz, 2014). Considering the vastness of this topic, we have chosen to concentrate on curcumin’s role in UPR regulation in NDs.
Curcumin as a Suppressor or Inducer of Unfolded Protein Response in Neurological Diseases
Curcumin Function in Brain Injury
Diffuse axonal injury (DAI) associated with abnormally expressed β-APP and p-tau proteins in neurons leds to ER-stress induced cell death. Curcumin treatment in rat DAI model increased PERK phosphorylation and decreased CHOP expression and therefore prevented aberrant protein accumulation and inhibited UPR pathway activation (Huang et al., 2018). In another study, curcumin protected against glutamate-induced hippocampus neurotoxicity. The therapeutic role of curcumin against various human diseases are well explored (Shakeri et al., 2019).
Mutation Associated Neuropathies
Besides having a protective impact on brain injuries, curcumin treatment has also improved peripheral neuropathies. For example, Trembler-J is caused by accumulation of mutated myelin proteins (PMP22) that led to ER stress, UPR activation, and Schwann cell death, which were minimized by curcumin treatment (Okamoto et al., 2013). The second most prevalent autosomal dominant hereditary demyelinating neuropathy is Charcot–Marie–Tooth disease type 1B (CMT1B), caused by activation of UPR components coupled with accumulation of mutant protein myelin protein Zero (P0, MPZ), as a consequence of ER stress (Santoro et al., 2004; Khajavi et al., 2005; Saporta et al., 2011). Using the CMT1B mouse model of human neuropathy, researchers discovered that these mice exhibited motor impairment and axonal abnormalities linked with aberrant UPR activation (Patzkó et al., 2012). It was noted that curcumin formulation could influence the treatment outcomes. Oral curcumin in sesame oil enhanced neurophysiological state and Schwann cell myelination in CMT1B mouse model with decreased UPR signaling (Patzkó et al., 2012). Using the HT22 mouse hippocampus cell line, Chhunchha et al. (2013) discovered that curcumin has anti-oxidative and anti-ER stress properties. Curcumin therapy increased peroxiredoxin 6 (Prdx6) expressions and decreased ER stress in hypoxic HT22 cells (Chhunchha et al., 2013). ApoE4 is the major genetic risk factor for AD associated with dementia. Kou et al. (2021) found that ApoE4 transgenic mice had impaired cognitive capacity, which is linked to ER stress and activation of inflammatory signaling in the nervous system; these were reversed by curcumin treatment in AD mice. Curcumin is also found effective in Pelizaeus-Merzbacher disease of mice model (Gow et al., 1998; Hübner et al., 2005; Yu et al., 2012).
Analogs of Curcumin and Unfolded Protein Response in Neurological Diseases
The low bioavailability of curcumin leads to its poor absorption, requiring large doses of curcumin to reach a definite level in plasma. Curcumin plasma levels have been improved by dissolving it in various solutions, coating it with nanoparticles, forming emulsions and by creating its analogs (Sasaki et al., 2011; Zhongfa et al., 2012; Ramalingam and Ko, 2015). There are multiple curcumin analogs have been generated those presented profound effect in modulating ER stress in various cancers model including ovarian, colon, lung, prostrate, gastric, acute promyelocytic leukemia, glioblastoma, melanoma, and triple negative breast cancer cells (Zhang et al., 2012; Qu et al., 2013; Tan et al., 2014; Yoon et al., 2014; Zheng et al., 2014; Chen et al., 2016; Gao et al., 2017; He et al., 2021). However, curcumin mimics’ effects on neurodegenerative disorders are poorly documented.
Treatment with CNB-001, a curcumin derivative, reduced intracellular soluble-amyloid build up in AD transgenic mice by activating the UPR’s eIF2/ATF4 signaling (Valera et al., 2013). Protein disulfide isomerase (PDI) is an ER-resident chaperone that is modified to S-nitroso-PDI in the presence of high levels of nitric oxide (NO), which disrupts PDI’s redox activity and resulted in the accumulation of misfolded in AD and PD model (Uehara et al., 2006). Curcumin analog 3,5-bis (2-flurobenzylidene) piperidin-4-one (EF-24) pretreatment of neuroblastoma cell line SHSY-5Y cells prevented rotenone-induced (a mitochondrial reactive oxygen species elevator) reduction in PDI expression and ER stress associated protein aggregation (Pal et al., 2011). Glioblastoma is the most common, highly invasive and malignant form of brain cancer currently treated with surgery, radiotherapy and chemotherapy. In a study published by Sansalone et al. (2019) have generated 19 curcumin analogs, out of which 4 have induced glioma stem cells (GSC) death and prevented neurosphere formation. Mechanistically, curcumin analog robustly induced UPR signaling as detected by increased expression of CHOP, p-jun and caspase 12 markers (Sansalone et al., 2019). Another study by Hackler et al. (2016) has demonstrated the cytotoxic effect of curcumin derivative C-150 (Mannich-type) on eight glioma cell lines. C-150 treatment in gliomas cells significantly affected expression of UPR proteins, Akt, and PKCα activity.
Overall, curcumin and its derivatives are neuroprotective in various neurological disorders and kill cancer cells via modulating UPR signaling (Table 1). The main difficulty is to formulate curcumin or its counterpart in the correct dosage and administer it in a proper manner. This includes undoubtedly to overcome poor absorption, rapid metabolism and poor bioavailability of curcumin and substantially improve its beneficial activities.
TABLE 1
| Compound | Disease type/cell line | Effects on ER stress markers and UPR signaling | References |
| Curcumin | DAI model of rat | ↑ (Nrf2, p-PERK), ↓ (CHOP) | Huang et al., 2018 |
| Curcumin | Hippocampus or SH-SY5Y cells | ↑ (AMPK), ↓ (p-IRE1α, p-PERK, NLRP3, TXNIP/NLRP3) | Li et al., 2015 |
| Curcumin | Mouse hippocampus cell HT22 | ↑ Prdx6, CHOP, Grp78), ↓ (ROS) | Valera et al., 2013 |
| Curcumin | Pmp22 Trembler-J mice | ↓ (Atf3 and Ero1-lβ) | Okamoto et al., 2013 |
| Curcumin dissolved in sesame oil or phosphatidylcholine | MPZR98C knock-in mice | ↓ (Bip, ATF6, spliced XBP1), no change in CHOP expression | Patzkó et al., 2012 |
| Curcumin | ApoE4 transgenic mice (SCXK2016-0004) | ↓ (NFkβ, APoE4, Grp78, IRE1α) | Kou et al., 2021 |
| Curcumin | Transgenic myelin synthesis deficient model | No changes in expression of Grp78, CHOP, Gadd45a, calnexin, calreticulin, Herpud1 | Yu et al., 2012 |
| CNB-001 (Curcumin analog) | huAPPswe/PS1E9 transgenic mice and MC65 cells | ↑ (p-PERK, eIF2α, HSP90, ATF4), ↓ (5-LOX, β-amyloid) | Valera et al., 2013 |
| EF-24 (Curcumin analog) | SHSY-5Y | ↑ (PDI expression), ↓ (AD associated protein aggregation) | Pal et al., 2011 |
| Bis-chalcone 4j (Curcumin analog) | GSC lines Glio3, Glio4, Glio9, Glio11 and Glio14 | ↑ (CHOP, p-jun and caspase 12) | Sansalone et al., 2019 |
| C-150 (Curcumin analog) | GBM1-6, U87 MG, U251 MG and U373 MG | ↑ (Grp78, GADD153, ATF4, XBP1), ↓ (NFkβ, Akt, PKCα kinase activity) | Hackler et al., 2016 |
Curcumin and its analogs are associated with UPR modulation in neurological disorders.
DAI, diffuse axonal injury; Nrf2, nuclear factor erythroid-derived 2-like 2; CHOP, CCAAT-enhancer-binding protein homologous protein; AMPK, AMP-activated protein kinase; NLRP3, NLR family pyrin domain containing 3; ApoE4, Apolipoprotein E4; GSC, glioma stem cells; AD, Alzheimer’s disease; XBP1, X-binding protein-1; ATF, activating transcription factor; Grp78, 78-kDa glucose-regulated protein; PDI, protein disulfide-isomerase; HSP90, heat shock protein 90; GADD153, growth arrest- and DNA damage-inducible gene 153; PKCα, protein kinase C; eIF2α, eukaryotic translation initiation factor 2A; Bip, binding immunoglobulin protein; Ero1, endoplasmic oxidoreductin-1; Prdx6, peroxiredoxin-6; ROS, reactive oxygen species.
Curcumin, Unfolded Protein Response and Neurodegenerative Diseases: A Trivial Connection and Future Perspectives
The studies suggest that deregulation of proteostasis, particularly aberrant UPR signaling, may be a common pathogenic mechanism in the development of ND. While modulation of the UPR in animal illness models, including AD, has shown early promises. To determine whether UPR signaling is a protective mechanism or actively contributes to disease development, neuropathological data alone cannot be used. The idea of targeting the UPR, and specifically the PERK signaling is extremely interesting (Das et al., 2015). Some protein misfolding in NDs appear to benefit from selectively increasing protein synthesis upstream or downstream of eIF2a-P to avoid pancreatic toxicity associated with systemic PERK inhibition.
Researchers also discovering novel UPR activation methods, e.g., mitochondria-associated ER membranes are gaining popularity as a possible therapeutic target in NDs. Disrupted connections between the ER and mitochondria have been identified were curcumin seems to influence ER-mitochondrial interactions (Paillusson et al., 2016). Curcumin as licensed drug delaying the development of dementia in different model systems, this is an intriguing idea and a major step forward in the quest for a therapeutic agent for neurodegeneration. The next issue will be identifying how best and when to regulate the PERK pathway in patients, given that there are many proven therapeutic targets along the route. What remains unclear if curcumin may directly interfere in neurodegeneration without engaging UPR components?
Curcumin affect the action of many factors such as NF-κ B and AP-1 (Han et al., 2002). Curcumin binds to different proteins and enzymes and modulate their conformation and biological activities. Curcumin’s linker length and flexibility make it ideal for binding to Aβ aggregates. Curcumin’s unique structure, which consists of an, α, β-unsaturated β-diketone moiety linked by a seven carbon heptadiene chain, allows it to remain in keto–enol tautomeric forms in solution depending on the pH. When the pH is between 3 and 7, it is in the keto form, whereas the enol form is found around pH 8. Curcumin retains its coplanarity and extends the double-bond conjugation through six membered hydrogen bonding at the center when it is in the enol form which has strong Aβ aggregate binding activities. Curcumin, on the other hand, has very low binding activities for Aβ aggregates when it is in the keto form. Studies have shown that to be able to bind to Aβ aggregates, compounds need to be coplanar and have a double-bond conjugation of certain length. Curcumin, however, has certain disadvantages too, which includes its low water solubility and bioavailability. Dissolving it into organic solvent improves it solubility but its absorption remains poor (Ege, 2021; Jia et al., 2021). Some recent articles addressed the methods to enhance curcumin’s effectiveness in treating AD (Fan et al., 2018; Francesco et al., 2019; Ege, 2021). In future curcumin compounds must be chemically screened on target enzymes and proteins to facilitate more information.
Overall, the studies suggest that curcumin may prevents or postpones the onset of NDs by decreasing ER stress which seems to be responsible for NDs through a complicated processes (Figure 1). Additional mechanistic studies are needed to establish curcumin’s role in reducing ER stress. Despite promising preclinical findings, there are currently no clinical data to support curcumin as part of a drug therapy against NDs. The recent rise in the number of NDs patients across the globe suggests that researchers and practitioners will need to discover an effective pharmaceutical medication or therapy to successfully treat these illnesses in the future. Curcumin’s interaction and mechanism of action against NDs warrants a more research to accomplish this goal.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
NJ, RP, AP, and SK contributed to the conception and design of the study. SM, AM, GP, NJ, and AP organized the material and wrote the first draft of the manuscript. SM, GP, SB, SH, NJ, and AP wrote sections of the manuscript. RP, VR, NJ, AP, and SK helped with manuscript editing and formatting. All authors contributed to manuscript revision, read, and approved the submitted version.
Funding
NJ was supported by the Ramalingaswami grant (BT/RLF/Re-entry/18/2017) from the Department of Biotechnology, Ministry of Science and Technology, Government of India. AP was supported by the Planning and Budgeting Committee (PBC) outstanding postdoctoral fellowship, Israel.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Abdel-Diam M. M. Samak D. H. El-Sayed Y. S. Aleya L. Alarifi S. Alkahtani S. (2019). Curcumin and quercetin synergistically attenuate subacute diazinon-induced inflammation and oxidative neurohepatic damage, and acetylcholinesterase inhibition in albino rats.Environ. Sci. Pollut. Res. Int.263659–3665. 10.1007/S11356-018-3907-9
2
Aggarwal B. B. Harikumar K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.Int. J. Biochem. Cell Biol.4140–59. 10.1016/j.biocel.2008.06.010
3
Ahmadi R. Salari S. Sharifi M. D. Reihani H. Rostamiani M. B. Behmadi M. et al (2021). Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial.Food Sci. Nutr.94068–4075. 10.1002/FSN3.2226
4
Barzegar A. Moosavi-Movahedi A. A. (2011). Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin.PLoS One6:26012. 10.1371/journal.pone.0026012
5
Begum A. N. Jones M. R. Lim G. P. Morihara T. Kim P. Heath D. D. et al (2008). Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease.J. Pharmacol. Exp. Ther.326196–208. 10.1124/jpet.108.137455
6
Bernardo A. Plumitallo C. De Nuccio C. Visentin S. Minghetti L. (2021). Curcumin promotes oligodendrocyte differentiation and their protection against TNF-α through the activation of the nuclear receptor PPAR-γ.Sci. Rep.11:4952.
7
Breydo L. Wu J. W. Uversky V. N. (2012). A -synuclein misfolding and Parkinson’s disease.Biochim. Biophys. Acta1822261–285. 10.1016/J.BBADIS.2011.10.002
8
Brunden K. R. Ballatore C. Crowe A. Smith A. B. Lee V. M. Y. Trojanowski J. Q. (2010). Tau-directed drug discovery for Alzheimer’s disease and related tauopathies: A focus on tau assembly inhibitors.Exp. Neurol.223304–310. 10.1016/j.expneurol.2009.08.031
9
Caughey B. Raymond L. D. Raymond G. J. Maxson L. Silveira J. Baron G. S. (2003). Inhibition of Protease-Resistant Prion Protein Accumulation In Vitro by Curcumin.J. Virol.775499–5502. 10.1128/jvi.77.9.5499-5502.2003
10
Chen W. Zou P. Zhao Z. Weng Q. Chen X. Ying S. et al (2016). Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation.Oncotarget716593–16609. 10.18632/oncotarget.7565
11
Cheng K. K. Yeung C. F. Ho S. W. Chow S. F. Chow A. H. L. Baum L. (2013). Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in alzheimer’s disease Tg2576 Mice.AAPS J.15324–336. 10.1208/s12248-012-9444-4
12
Chhunchha B. Fatma N. Kubo E. Rai P. Singh S. P. Singh D. P. (2013). Curcumin abates hypoxia-induced oxidative stress based-ER stress-mediated cell death in mouse hippocampal cells (HT22) by controlling Prdx6 and NF-κB regulation.Am. J. Physiol. Cell Physiol.304C636–C655. 10.1152/ajpcell.00345.2012
13
Chiti F. Dobson C. (2017). Protein Misfolding amyloid formation, and Human Disease: a summary of progress over the last decade.Annu. Rev. Biochem.8627–68. 10.1146/ANNUREV-BIOCHEM-061516-045115
14
Cho J. W. Lee K. S. Kim C. W. (2007). Curcumin attenuates the expression of IL-1β, IL-6, and TNF-α as well as cyclin E in TNF-α-treated HaCaT cells; NF-κB and MAPKs as potential upstream targets.Int. J. Mol. Med.19469–474. 10.3892/ijmm.19.3.469
15
Chyung J. H. Raper D. M. Selkoe D. J. (2005). Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage.J. Biol. Chem.2804383–4392. 10.1074/jbc.M409272200
16
Ciechanover A. Kwon Y. (2017). Protein Quality Control by Molecular Chaperones in Neurodegeneration.Front. Neurosci11:185. 10.3389/FNINS.2017.00185
17
Clayton D. F. George J. M. (1999). Synucleins in Synaptic Plasticity and Neurodegenerative Disorders.J. Neurosci. Res58120–129. 10.1002/(SICI)1097-4547(19991001)58
18
Cole G. M. Morihara T. Lim G. P. Yang F. Begum A. Frautschy S. A. (2004). NSAID and antioxidant prevention of Alzheimer’s disease: lessons from in vitro and animal models.Ann. N. Y. Acad. Sci.103568–84. 10.1196/annals.1332.005
19
Cole G. M. Teter B. Frautschy S. A. (2007). Neuroprotective effects of curcumin.Adv. Exp. Med. Biol.595197–212. 10.1007/978-0-387-46401-5_8
20
Das I. Krzyzosiak A. Schneider K. Wrabetz L. D’Antonio M. Barry N. et al (2015). Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit.Science348239–242. 10.1126/science.aaa4484
21
Desai P. P. Patravale V. B. (2018). Curcumin Cocrystal Micelles—Multifunctional Nanocomposites for Management of Neurodegenerative Ailments.J. Pharm. Sci.1071143–1156. 10.1016/j.xphs.2017.11.014
22
Dong W. Yang B. Wang L. Li B. Guo X. Zhang M. et al (2018). Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling.Toxicol. Appl. Pharmacol.34628–36. 10.1016/j.taap.2018.03.020
23
Durairajan S. S. K. Liu L.-F. Lu J.-H. Chen L.-L. Yuan Q. Chung S. K. et al (2012). Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer’s disease transgenic mouse model.Neurobiol. Aging332903–2919. 10.1016/j.neurobiolaging.2012.02.016
24
Ege D. (2021). Action Mechanisms of Curcumin in Alzheimer’s Disease and Its Brain Targeted Delivery.Mater14:332. 10.3390/MA14123332
25
Eghbaliferiz S. Farhadi F. Barreto G. E. Majeed M. Sahebkar A. (2020). Effects of curcumin on neurological diseases: focus on astrocytes.Pharmacol. Rep.72769–782. 10.1007/s43440-020-00112-3
26
Fan Y. Yi J. Zhang Y. Yokoyama W. (2018). Fabrication of curcumin-loaded bovine serum albumin (BSA)-dextran nanoparticles and the cellular antioxidant activity.Food Chem.2391210–1218. 10.1016/j.foodchem.2017.07.075
27
Feigin V. Emma N. Tahiya A. Marlena S. B. Gbd 2016 Neurology Collaborators. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol.18459–480. 10.1016/S1474-4422(18)30499-X
28
Forouzanfar F. Read M. I. Barreto G. E. Sahebkar A. (2020). Neuroprotective effects of curcumin through autophagy modulation.IUBMB Life72652–664. 10.1002/iub.2209
29
Francesco D. M. Margarucci S. Galderisi U. Crispi S. Peluso G. (2019). Curcumin, gut microbiota, and neuroprotection.Nutrients11:2426. 10.3390/nu11102426
30
Frautschy S. A. Hu W. Kim P. Miller S. A. Chu T. Harris-White M. E. et al (2001). Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology.Neurobiol. Aging22993–1005. 10.1016/S0197-4580(01)00300-1
31
Gammon K. (2014). Neurodegenerative disease: brain windfall.Nature515299–300. 10.1038/NJ7526-299A
32
Ganguli M. Chandra V. Kamboh M. I. Johnston J. M. Dodge H. H. Thelma B. K. et al (2000). Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study.Arch. Neurol.57824–830. 10.1001/archneur.57.6.824
33
Gao J. Fan M. Peng S. Zhang M. Xiang G. Li X. et al (2017). Small-molecule RL71-triggered excessive autophagic cell death as a potential therapeutic strategy in triple-negative breast cancer.Cell Death Dis.8:e3049. 10.1038/cddis.2017.444
34
Garcia-Alloza M. Borrelli L. A. Rozkalne A. Hyman B. T. Bacskai B. J. (2007). Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.J. Neurochem.1021095–1104. 10.1111/j.1471-4159.2007.04613.x
35
Gow A. Southwood C. M. Lazzarini R. A. (1998). Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease.J. Cell Biol.140925–934. 10.1083/jcb.140.4.925
36
Gregory J. Vengalasetti Y. V. Bredesen D. E. Rao R. V. (2021). Neuroprotective herbs for the management of alzheimer’s disease.Biomolecules11:543. 10.3390/biom11040543
37
Gupta S. C. Patchva S. Aggarwal B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials.AAPS J.15195–218. 10.1208/s12248-012-9432-8
38
Haass C. Selkoe D. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide.Nat. Rev. Mol. Cell Biol.8101–112. 10.1038/NRM2101
39
Hackler L. Ózsvári B. Gyuris M. Sipos P. Fábián G. Molnár E. et al (2016). The Curcumin Analog C-150, Influencing NF-κB, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo.PLoS One11:e0149832. 10.1371/journal.pone.0149832
40
Han S.-S. Keum Y.-S. Seo H.-J. Surh Y.-J. (2002). Curcumin Suppresses Activation of NF-κB and AP-1 Induced by Phorbol Ester in Cultured Human Promyelocytic Leukemia Cells.J. Biochem. Mol. Biol.35337–342.
41
He Y. Li W. Zhang J. Yang Y. Qian Y.-W. Zhou D. (2021). The curcumin analog EF24 is highly active against chemotherapy-resistant melanoma cells.Curr. Cancer Drug Targets21608–618. 10.2174/1568009621666210303092921
42
Heneka M. T. Sastre M. Dumitrescu-Ozimek L. Hanke A. Dewachter I. Kuiperi C. et al (2005). Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.Brain1281442–1453. 10.1093/brain/awh452
43
Hetz C. Chevet E. Harding H. P. (2013). Targeting the unfolded protein response in disease.Nat. Rev. Drug Discov.129703–719. 10.1038/nrd3976
44
Hetz C. Mollereau B. (2014). Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases.Nat. Rev. Neurosci.15233–249. 10.1038/NRN3689
45
Hetz C. Papa F. (2018). The Unfolded Protein Response and Cell Fate Control.Mol. Cell69169–181. 10.1016/J.MOLCEL.2017.06.017
46
Hetz C. Zhang K. Kaufman R. J. (2020). Mechanisms, regulation and functions of the unfolded protein response.Nat. Rev. Mol. Cell Biol.21421–438. 10.1038/s41580-020-0250-z
47
Hewlings S. Kalman D. (2017). Curcumin: A Review of Its Effects on Human Health.Foods6:92. 10.3390/FOODS6100092
48
Hoozemans J. J. M. van Haastert E. S. Eikelenboom P. de Vos R. A. I. Rozemuller J. M. Scheper W. (2007). Activation of the unfolded protein response in Parkinson’s disease.Biochem. Biophys. Res. Commun.354707–711. 10.1016/j.bbrc.2007.01.043
49
Huang P. Zheng N. Zhou H.-B. Huang J. (2020). Curcumin inhibits BACE1 expression through the interaction between ERβ and NFκB signaling pathway in SH-SY5Y cells.Mol. Cell. Biochem.463161–173. 10.1007/s11010-019-03638-0
50
Huang T. Zhao J. Guo D. Pang H. Zhao Y. Song J. (2018). Curcumin mitigates axonal injury and neuronal cell apoptosis through the PERK/Nrf2 signaling pathway following diffuse axonal injury.Neuroreport29661–677. 10.1097/WNR.0000000000001015
51
Hübner C. A. Orth U. Senning A. Steglich C. Kohlschütter A. Korinthenberg R. et al (2005). Seventeen novel PLP1 mutations in patients with Pelizaeus-Merzbacher disease.Hum. Mutat.25321–322. 10.1002/humu.9314
52
Jia F. Chibhabha F. Yang Y. Kuang Y. Zhang Q. Ullah S. et al (2021). Detection and monitoring of the neuroprotective behavior of curcumin micelles based on an AIEgen probe.J. Mater. Chem. B9731–745. 10.1039/d0tb02320e
53
Kakkar V. Meister-Broekema M. Minoia M. Carra S. Kampinga H. H. (2014). Barcoding heat shock proteins to human diseases: looking beyond the heat shock response.Dis. Model. Mech.7421–434. 10.1242/dmm.014563
54
Karlstetter M. Lippe E. Walczak Y. Moehle C. Aslanidis A. Mirza M. et al (2011). Curcumin is a potent modulator of microglial gene expression and migration.J. Neuroinfl.81–12. 10.1186/1742-2094-8-125
55
Khajavi M. Inoue K. Wiszniewski W. Ohyama T. Snipes G. J. Lupski J. R. (2005). Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants.Am. J. Hum. Genet.77841–850. 10.1086/497541
56
Kheirouri S. Alizadeh M. (2019). Dietary Inflammatory Potential and the Risk of Neurodegenerative Diseases in Adults.Epidemiol. Rev.41109–120. 10.1093/EPIREV/MXZ005
57
Kim H. Park B. S. Lee K. G. Cheol Y. C. Sung S. J. Kim Y. H. et al (2005). Effects of naturally occurring compounds on fibril formation and oxidative stress of β-amyloid.J. Agric. Food Chem.538537–8541. 10.1021/jf051985c
58
Kou J. Wang M. Shi J. Zhang H. Pu X. Song S. et al (2021). Curcumin Reduces Cognitive Deficits by Inhibiting Neuroinflammation through the Endoplasmic Reticulum Stress Pathway in Apolipoprotein E4 Transgenic Mice.ACS Omega66654–6662. 10.1021/acsomega.0c04810
59
Landau M. Sawaya M. R. Faull K. F. Laganowsky A. Jiang L. Sievers S. A. et al (2011). Towards a pharmacophore for amyloid.PLoS Biol.9:e1001080. 10.1371/journal.pbio.1001080
60
Lee S.-J. Lim H.-S. Masliah E. Lee H.-J. (2011). Protein aggregate spreading in neurodegenerative diseases: problems and perspectives.Neurosci. Res.70339–348. 10.1016/j.neures.2011.05.008
61
Lestari M. L. A. D. Indrayanto G. (2014). Curcumin.Profiles Drug Subst.Excip. Relat. Methodol.39113–204. 10.1016/B978-0-12-800173-8.00003-9
62
Li H. Dai Y. Wu H. Luo L. Wei L. Zhou L. et al (2020). Predictors of Early Neurologic Deterioration in Acute Pontine Infarction.Stroke51637–640. 10.1161/STROKEAHA.119.027239
63
Li Y. Li J. Li S. Li Y. Wang X. Liu B. et al (2015). Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK.Toxicol. Appl. Pharmacol.28653–63. 10.1016/j.taap.2015.03.010
64
Lim G. P. Chu T. Yang F. Beech W. Frautschy S. A. Cole G. M. (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.J. Neurosci.218370–8377. 10.1523/jneurosci.21-21-08370.2001
65
Limonta P. Moretti R. M. Marzagalli M. Fontana F. Raimondi M. Montagnani Marelli M. (2019). Role of Endoplasmic Reticulum Stress in the Anticancer Activity of Natural Compounds.Int. J. Mol. Sci.20:961. 10.3390/ijms20040961
66
Lin R. Chen X. Li W. Han Y. Liu P. Pi R. (2008). Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: Blockage by curcumin.Neurosci. Lett.440344–347. 10.1016/j.neulet.2008.05.070
67
Ma Q.-L. Zuo X. Yang F. Ubeda O. J. Gant D. J. Alaverdyan M. et al (2013). Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.J. Biol. Chem.2884056–4065. 10.1074/jbc.M112.393751
68
Mahul-Mellier A.-L. Burtscher J. Maharjan N. Weerens L. Croisier M. Kuttler F. et al (2020). The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.Proc. Natl. Acad. Sci. U.S.A.1174971–4982. 10.1073/pnas.1913904117
69
Marton L. T. Barbalho S. M. Sloan K. P. Sloan L. A. Goulart R. de A. et al (2020). Curcumin, autoimmune and inflammatory diseases: going beyond conventional therapy - a systematic review.Crit. Rev. Food Sci. Nutr.11–19. 10.1080/10408398.2020.1850417
70
McClure R. Ong H. Janve V. Barton S. Zhu M. Li B. et al (2017). Aerosol Delivery of Curcumin Reduced Amyloid-β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer’s Disease.J. Alzheimer’s Dis.55797–811. 10.3233/JAD-160289
71
Mei X. Zhu L. Zhou Q. Li X. Chen Z. (2020). Interplay of curcumin and its liver metabolism on the level of Aβ in the brain of APPswe/PS1dE9 mice before AD onset.Pharmacol. Rep.721604–1613. 10.1007/s43440-020-00116-z
72
Mishra K. Palanivelu K. (2008). The effect of curcumin (turmeric) on Alzheimer’s disease: An overview.Ann. Indian Acad. Neurol.1113–19. 10.4103/0972-2327.40220
73
Mohorko N. Repovs G. Popović M. Kovacs G. G. Bresjanac M. (2010). Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples.J. Neuropathol. Exp. Neurol.69405–414. 10.1097/NEN.0b013e3181d709eb
74
Mutsuga M. Chambers J. K. Uchida K. Tei M. Makibuchi T. Mizorogi T. et al (2012). Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer’s brain.J. Vet. Med. Sci.7451–57. 10.1292/jvms.11-0307
75
Nebrisi E. El, Javed H. Ojha S. K. Oz M. Shehab S. (2020). Neuroprotective effect of curcumin on the nigrostriatal pathway in a 6-hydroxydopmine-induced rat model of parkinson’s disease is mediated by α7-nicotinic receptors.Int. J. Mol. Sci.211–19. 10.3390/ijms21197329
76
Noorafshan A. Ashkani-Esfahani S. (2013). A Review of Therapeutic Effects of Curcumin.Curr. Pharm. Des.192032–2046. 10.2174/138161213805289273
77
Okamoto Y. Pehlivan D. Wiszniewski W. Beck C. R. Snipes G. J. Lupski J. R. et al (2013). Curcumin facilitates a transitory cellular stress response in Trembler-J mice.Hum. Mol. Genet.224698–4705. 10.1093/hmg/ddt318
78
Ono K. Hasegawa K. Naiki H. Yamada M. (2004). Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro.J. Neurosci. Res.75742–750. 10.1002/jnr.20025
79
Paillusson S. Stoica R. Gomez-Suaga P. Lau D. H. W. Mueller S. Miller T. et al (2016). There’s Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases.Trends Neurosci.39146–157. 10.1016/j.tins.2016.01.008
80
Pal R. Miranda M. Narayan M. (2011). Nitrosative stress-induced Parkinsonian Lewy-like aggregates prevented through polyphenolic phytochemical analog intervention.Biochem. Biophys. Res. Commun.404324–329. 10.1016/j.bbrc.2010.11.117
81
Pandey N. Strider J. Nolan W. C. Yan S. X. Galvin J. E. (2008). Curcumin inhibits aggregation of α-synuclein.Acta Neuropathol.115479–489. 10.1007/s00401-007-0332-4
82
Patzkó A. Bai Y. Saporta M. A. Katona I. Wu X. Vizzuso D. et al (2012). Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice.Brain1353551–3566. 10.1093/brain/aws299
83
Pohl F. Kong Thoo Lin P. (2018). The Potential Use of Plant Natural Products and Plant Extracts with Antioxidant Properties for the Prevention/Treatment of Neurodegenerative Diseases: In Vitro, In Vivo and Clinical Trials.Molecules23:3283. 10.3390/MOLECULES23123283
84
Qu W. Xiao J. Zhang H. Chen Q. Wang Z. Shi H. et al (2013). B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway.Int. J. Biol. Sci.9766–777. 10.7150/ijbs.5711
85
Radbakhsh S. Barreto G. E. Bland A. R. Sahebkar A. (2021). Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes.Biofactors47570–586. 10.1002/biof.1735
86
Ramalingam P. Ko Y. (2015). Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations.Pharm. Res.32389–402. 10.1007/S11095-014-1469-1
87
Reddy R. C. Vatsala P. G. Keshamouni V. G. Padmanaban G. Rangarajan P. N. (2005). Curcumin for malaria therapy.Biochem. Biophys. Res. Commun.326472–474. 10.1016/j.bbrc.2004.11.051
88
Reeta K. H. Mehla J. Gupta Y. K. (2010). Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.Eur. J. Pharmacol.644106–112. 10.1016/j.ejphar.2010.07.022
89
Ryskalin L. Puglisi-Allegra S. Lazzeri G. Biagioni F. Busceti C. L. Balestrini L. et al (2021). Neuroprotective effects of curcumin in methamphetamine-induced toxicity.Molecules26:2493. 10.3390/molecules26092493
90
Sano R. Reed J. (2013). ER stress-induced cell death mechanisms.Biochim. Biophys. Acta18333460–3470. 10.1016/J.BBAMCR.2013.06.028
91
Sansalone L. Veliz E. A. Myrthil N. G. Stathias V. Walters W. Torrens I. I. et al (2019). Novel Curcumin Inspired Bis-Chalcone Promotes Endoplasmic Reticulum Stress and Glioblastoma Neurosphere Cell Death.Cancers11:E357. 10.3390/cancers11030357
92
Santoro L. Manganelli F. Maria E. Di, Bordo D. Cassandrini D. et al (2004). A novel mutation of myelin protein zero associated with an axonal form of Charcot–Marie–Tooth disease.J. Neurol. Neurosurg. Psychiatry75262–265. 10.1136/JNNP.2003.012278
93
Saporta A. S. D. Sottile S. L. Miller L. J. Feely S. M. E. Siskind C. E. Shy M. E. (2011). Charcot-Marie-Tooth disease subtypes and genetic testing strategies.Ann. Neurol.6922–33. 10.1002/ana.22166
94
Sasaki H. Sunagawa Y. Takahashi K. Imaizumi A. Fukuda H. Hashimoto T. et al (2011). Innovative preparation of curcumin for improved oral bioavailability.Biol. Pharm. Bull.34660–665. 10.1248/bpb.34.660
95
Schapira A. (1999). Science, medicine, and the future: Parkinson’s disease.BMJ318311–314. 10.1136/BMJ.318.7179.311
96
Scheper W. Hoozemans J. (2015). The unfolded protein response in neurodegenerative diseases: a neuropathological perspective.Acta Neuropathol.130315–331. 10.1007/S00401-015-1462-8
97
Schwarz D. Blower M. (2016). The endoplasmic reticulum: structure, function and response to cellular signaling.Cell. Mol. Life Sci.7379–94. 10.1007/S00018-015-2052-6
98
Serafini M. M. Catanzaro M. Rosini M. Racchi M. Lanni C. (2017). Curcumin in Alzheimer’s disease: Can we think to new strategies and perspectives for this molecule?Pharmacol. Res.124146–155. 10.1016/j.phrs.2017.08.004
99
Shah S. Z. A. Zhao D. Khan S. H. Yang L. (2015). Unfolded Protein Response Pathways in Neurodegenerative Diseases.J. Mol. Neurosci.57529–537. 10.1007/s12031-015-0633-3
100
Shakeri A. Zirak M. R. Wallace Hayes A. Reiter R. Karimi G. (2019). Curcumin and its analogues protect from endoplasmic reticulum stress: Mechanisms and pathways.Pharmacol. Res.146:104335. 10.1016/J.PHRS.2019.104335
101
Shamsi T. N. Athar T. Parveen R. Fatima S. (2017). A review on protein misfolding, aggregation and strategies to prevent related ailments.Int. J. Biol. Macromol.105993–1000. 10.1016/j.ijbiomac.2017.07.116
102
Sharifi-Rad J. Rayess Y. El, Rizk A. A. Sadaka C. Zgheib R. et al (2020). Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications.Front. Pharmacol.11:1021. 10.3389/FPHAR.2020.01021
103
Silvestro S. Sindona C. Bramanti P. Mazzon E. (2021). A state of the art of antioxidant properties of curcuminoids in neurodegenerative diseases.Int. J. Mol. Sci.221–26. 10.3390/ijms22063168
104
Simeonova R. Zheleva D. Valkova I. Stavrakov G. Philipova I. Atanasova M. et al (2021). A novel galantamine-curcumin hybrid as a potential multi-target agent against neurodegenerative disorders.Molecules26:1865. 10.3390/molecules26071865
105
Singh S. Aggarwal B. B. (1995). Activation of transcription factor NF-κB is suppressed by curcumin (diferulolylmethane).J. Biol. Chem.27024995–25000. 10.1074/jbc.270.42.24995
106
Smith H. Mallucci G. (2016). The unfolded protein response: mechanisms and therapy of neurodegeneration.Brain1392113–2121. 10.1093/BRAIN/AWW101
107
Su I. J. Chang H. Y. Wang H. C. Tsai K. J. (2020). A curcumin analog exhibits multiple biologic effects on the pathogenesis of Alzheimer’s disease and improves behavior, inflammation, and β-amyloid accumulation in a mouse model.Int. J. Mol. Sci.211–20. 10.3390/ijms21155459
108
Tan K.-L. Ali A. Du Y. Fu H. Jin H.-X. Chin T.-M. et al (2014). Synthesis and evaluation of bisbenzylidenedioxotetrahydrothiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells.J. Med. Chem.575904–5918. 10.1021/jm401352a
109
Tang M. Taghibiglou C. Liu J. (2017). The Mechanisms of Action of Curcumin in Alzheimer’s Disease.J. Alzheimer’s Dis.581003–1016. 10.3233/JAD-170188
110
Taniguchi M. Yoshida H. (2011). Unfolded Protein Response.Compr. Biotechnol.1525–537. 10.1016/B978-0-08-088504-9.00062-3
111
Taylor J. P. Hardy J. Fischbeck K. H. (2002). Toxic proteins in neurodegenerative disease.Science2961991–1995. 10.1126/science.1067122
112
Tiwari S. K. Agarwal S. Seth B. Yadav A. Nair S. Bhatnagar P. et al (2014). Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway.ACS Nano876–103. 10.1021/nn405077y
113
Uehara T. Nakamura T. Yao D. Shi Z.-Q. Gu Z. Ma Y. et al (2006). S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.Nature441513–517. 10.1038/nature04782
114
Urra H. Hetz C. (2014). A novel ER stress-independent function of the UPR in angiogenesis.Mol. Cell54542–544. 10.1016/J.MOLCEL.2014.05.013
115
Valera E. Dargusch R. Maher P. A. Schubert D. (2013). Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer’s disease.J. Neurosci.3310512–10525. 10.1523/JNEUROSCI.5183-12.2013
116
Vera-Ramirez L. Pérez-Lopez P. Varela-Lopez A. Ramirez-Tortosa M. Battino M. Quiles J. L. (2013). Curcumin and liver disease.BioFactors3988–100. 10.1002/biof.1057
117
Voulgaropoulou S. D. van Amelsvoort T. A. M. J. Prickaerts J. Vingerhoets C. (2019). The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies.Brain Res.1725146476. 10.1016/j.brainres.2019.146476
118
Wang H. M. Zhao Y. X. Zhang S. Liu G. D. Kang W. Y. Tang H. D. et al (2010). PPARγ agonist curcumin reduces the amyloid-β-stimulated inflammatory responses in primary astrocytes.J. Alzheimer’s Dis.201189–1199. 10.3233/JAD-2010-091336
119
Wang M. Kaufman R. (2016). Protein misfolding in the endoplasmic reticulum as a conduit to human disease.Nature529326–335. 10.1038/NATURE17041
120
Xu Y. X. Pindolia K. R. Janakiraman N. Chapman R. A. Gautam S. C. (1997). Curcumin inhibits IL1α and TNFα induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells.Hematopathol. Mol. Hematol.1149–62.
121
Yang F. Lim G. P. Begum A. N. Ubeda O. J. Simmons M. R. Ambegaokar S. S. et al (2005). Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo.J. Biol. Chem.2805892–5901. 10.1074/jbc.M404751200
122
Yoon M. J. Kang Y. J. Lee J. A. Kim I. Y. Kim M. A. Lee Y. S. et al (2014). Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin.Cell Death Dis.5:e1112. 10.1038/cddis.2014.85
123
Yu L.-H. Morimura T. Numata Y. Yamamoto R. Inoue N. Antalfy B. et al (2012). Effect of curcumin in a mouse model of Pelizaeus-Merzbacher disease.Mol. Genet. Metab.106108–114. 10.1016/j.ymgme.2012.02.016
124
Zhang C. Browne A. Child D. Tanzi R. E. (2010). Curcumin decreases amyloid-β peptide levels by attenuating the maturation of amyloid-β precursor protein.J. Biol. Chem.28528472–28480. 10.1074/jbc.M110.133520
125
Zhang X. Zhang H.-Q. Zhu G.-H. Wang Y.-H. Yu X.-C. Zhu X.-B. et al (2012). A novel mono-carbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production.Mol. Med. Rep.5739–744. 10.3892/mmr.2011.700
126
Zhao L. Ackerman S. (2006). Endoplasmic reticulum stress in health and disease.Curr. Opin. Cell Biol.18444–452. 10.1016/J.CEB.2006.06.005
127
Zheng A. Li H. Wang X. Feng Z. Xu J. Cao K. et al (2014). Anticancer effect of a curcumin derivative B63: ROS production and mitochondrial dysfunction.Curr. Cancer Drug Targets14156–166. 10.2174/1568009613666131126115444
128
Zhongfa L. Chiu M. Wang J. Chen W. Yen W. Fan-Havard P. et al (2012). Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice.Cancer Chemother. Pharmacol.69679–689. 10.1007/s00280-011-1749-y
Summary
Keywords
Alzheimer’s disease, Parkinson’s disease, neurodegenaration, unfolded protein response, ER stress, curcumin, ROS—reactive oxygen species, cell death
Citation
Mukherjee S, Mishra AK, Peer GDG, Bagabir SA, Haque S, Pandey RP, Raj VS, Jain N, Pandey A and Kar SK (2021) The Interplay of the Unfolded Protein Response in Neurodegenerative Diseases: A Therapeutic Role of Curcumin. Front. Aging Neurosci. 13:767493. doi: 10.3389/fnagi.2021.767493
Received
30 August 2021
Accepted
18 October 2021
Published
19 November 2021
Volume
13 - 2021
Edited by
Rinki Minakshi, University of Delhi, India
Reviewed by
Niraj Kumar Jha, Sharda University, India; Upendra Kumar Singh, La Jolla Institute for Immunology (LJI), United States
Updates
Copyright
© 2021 Mukherjee, Mishra, Peer, Bagabir, Haque, Pandey, Raj, Jain, Pandey and Kar.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Atul Pandey, atulkp@umich.eduSantosh Kumar Kar, santoshkariis@rediffmail.com
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.